Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial

Neurology

Volumn 80, Issue 8, 2013, Pages 697-704

  Schoenen, Jean ^a   Vandersmissen, Bart ^b   Jeangette, Sandrine ^c   Herroelen, Luc ^d   Vandenheede, Michel ^e   Gérard, Pascale ^a   Magis, Delphine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e CHC Espérance Liège ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; IMPLANTABLE NEUROSTIMULATOR; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NERVE STIMULATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SUPRAORBITAL TRANSCUTANEOUS STIMULATOR; TREATMENT RESPONSE; TRIGEMINAL NEUROSTIMULATION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84876231211     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182825055     Document Type: Article

References (25)

1. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-495.
2. Wall PD, Sweet WH. Temporary abolition of pain in man. Science 1967;155:108-109.
3. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007;14:952-970.
4. Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 2007;6:314-321.
5. Magis D, Gerardy PY, Remacle JM, Schoenen J. Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache. Headache 2011;51:1191-1201.
6. Reed KL, Black SB, Banta CJ II, Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010;30:260-271.
7. Solomon S, Guglielmo KM. Treatment of headache by trans-cutaneous electrical stimulation. Headache 1985;25:12-15.
8. Gérardy PY, Fabry D, Fumal A, Schoenen J. A pilot study on supra-orbital surface electrotherapy in migraine. Cephalalgia 2009;29:134.
9. The International classification of headache disorders: 2nd edition. Cephalalgia 2004;24 (suppl 1):9-160.
10. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010;9:373-380.
11. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31:271-285.
12. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28: 585-597.
13. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961-968.
14. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-786.
15. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004:CD003225.
16. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341:c4871.
17. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-973.
18. Silberstein S, Dodick D, Saper J, et al. The safety and efficacy of occipital nerve stimulation for the management of chronic migraine. Cephalalgia 2011;31(suppl 1):117.
19. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754-762.
20. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol 2009;16:968-981.
21. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1998;18:52-56.
22. Piquet M, Balestra C, Sava SL, Schoenen JE. Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects. BMC Neurol 2011;11:135.
23. Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004;127:220-230.
24. Magis D, Bruno MA, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stimulation: an FDG-PET study. BMC Neurol 2011;11:25.
25. May A. New insights into headache: an update on functional and structural imaging findings. Nat Rev Neurol 2009;5:199-209.